雷珠单抗治疗增殖性糖尿病视网膜病变患者的随访中断:随机临床试验事后分析
该事后分析基于美国55个中心305名成人增殖性糖尿病视网膜病变患者的随机临床试验数据,评估分配至雷珠单抗注射组患者的随访完成情况。5年随访中,170名参与者中55.3%至少发生一次长时间随访中断,29.4%失访;
要点
- 5年内55.3%的雷珠单抗治疗PDR患者至少发生一次≥8周的长时间随访中断。
- 29.4%的患者在5年内失访,但73.4%在首次长时间中断后返回检查。
核心结论
- 5年随访中约半数分配至雷珠单抗治疗PDR的参与者发生长时间随访中断,选择PDR治疗方案时需考虑长期随访中断的可能性。
研究设计与样本
- 多中心随机临床试验的事后分析,纳入美国55个中心305名成人增殖性糖尿病视网膜病变患者,共394只研究眼,2012年2月至12月入组。
- 170名参与者分配至玻璃体腔注射雷珠单抗治疗PDR或黄斑水肿,中位年龄51岁,44.7%为女性,随访至5年。
主要发现
- 170名参与者中94名(55.3%)在5年内发生至少一次长时间随访中断(超过预定检查8周或以上)。
- 首次长时间中断的中位时间为210周,94名中69名(73.4%)在首次长时间中断后返回检查。
关键数值与推荐
- 多变量调整后,基线视力评分每降低5个字母,发生至少一次长时间中断的比值比(95%CI)为1.21(1.03-1.43)。
- 视盘及别处新生血管的比值比(95%CI)为2.19(1.09-4.38)。
- 无既往糖尿病黄斑水肿激光治疗的比值比(95%CI)为3.48(1.38-8.78)。
临床怎么用
- 为PDR患者选择雷珠单抗治疗时,应评估其长期频繁随访和重复治疗的依从可能性。
- 基线视力较低、存在视盘及别处新生血管、无既往DME激光治疗者发生长时间随访中断的风险更高。
局限性
- 本文为事后分析,原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The follow-up schedule for individuals with eyes treated with anti-vascular endothelial growth factor agents for proliferative diabetic retinopathy (PDR) requires that patients return frequently for monitoring and repeated treatment. The likelihood that a patient will comply should be a consideration in choosing a treatment approach. OBJECTIVE: To describe completion of scheduled examinations among participants assigned to intravitreous injections of ranibizumab for PDR in a multicenter randomized clinical trial. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis evaluates data from a randomized clinical trial conducted at 55 US sites among 305 adults with proliferative diabetic retinopathy enrolled between February and December 2012. Both eyes were enrolled for 89 participants (1 eye to each study group), with a total of 394 study eyes. The final 2-year visit was completed in January 2015. Data were analyzed from April 2019 to July 2021. INTERVENTIONS: Ranibizumab injections for PDR or macular edema. MAIN OUTCOMES AND MEASURES: A long lapse in care of 8 or more weeks past a scheduled examination, dropout from follow-up, visual acuity at 5 years. RESULTS: Among 170 participants, the median age was 51 years, and 44.7% were female. Through 5 years of follow-up, 94 of 170 participants (55.3%) had 1 or more long lapse in care. Median time to the first long lapse was 210 weeks, and 69 of 94 participants (73.4%) returned for examination after the first long lapse. Fifty of 170 participants (29.4%) dropped out of follow-up by 5 years. Among the 120 participants who completed the 5-year examination, median change from baseline in visual acuity was -2 letters for participants who had 1 or more long lapse compared with +5 letters for those without a long lapse (P = .02). After multivariable adjustment, the odds ratio (95% CI) for baseline associations with 1 or more long lapse was 1.21 (1.03-1.43) for each 5-letter decrement in visual acuity score, 2.19 (1.09-4.38) for neovascularization of the disc and elsewhere, and 3.48 (1.38-8.78) for no prior laser treatment for diabetic macular edema. CONCLUSIONS AND RELEVANCE: Over 5 years, approximately half of the participants assigned to ranibizumab for PDR had a long lapse in care despite substantial effort by the DRCR Retina Network to facilitate timely completion of examinations. The likelihood of a long lapse in care during long-term follow-up needs to be considered when choosing treatment for PDR. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01489189.
引用
- Maguire MG, Liu D, Bressler SB, et al. Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 34673898. doi:10.1001/jamaophthalmol.2021.4103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。